explore -WSS

explore

author：Wikipedia 2025-10-01 18:33:44 - browse：32

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： How to convince healthy people to buy insurance

Wikipedia

WSS

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

A letter from the executive editor: The 2023 STATUS List

The biotech scorecard for Q3: 15 stock

Prime Medicine says its gene editing passes test in monkeys

Explaining an after

Prescription digital therapeutics are key to pharma’s future

focus

explore

entertainment

The high cost of giving birth even with insurance

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Drug repurposing or repositioning? The language matters

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Alkermes shareholders re

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Peter Hotez and the public health issue of online harassment

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

How to save PrEP access — and even expand it

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

entertainment

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

A letter from the executive editor: The 2023 STATUS List

Infant mortality in U.S. rose last year for first time in decades: CDC

Prescription digital therapeutics are key to pharma’s future

Infant mortality in U.S. rose last year for first time in decades: CDC

The biotech scorecard for Q3: 15 stock

knowledge

Wikipedia

hotspot

explore